FDA Rejects Ozanimod Application for Relapsing Multiple Sclerosis

Article

Ozanimod evaluated as a treatment for multiple sclerosis and inflammatory bowel disease.

Celgene Corporation announced it received a refusal to file letter from the FDA for a new drug application (NDA) for ozanimod for relapsing forms of multiple sclerosis (MS), according to a company press release.

Ozanimod is an investigational oral selective sphingosine 1-phosphate 1 and 5 receptor modulator that is being explored for the treatment of MS and other autoimmune conditions, including Crohn’s disease and ulcerative colitis.

The FDA rejected the application on the grounds of insufficient non-clinical and clinical pharmacology information for a review, according to the release.

Celgene plans to request a Type A meeting with the FDA to determine which information is required to resubmit the application for ozanimod. The drug has yet to be approved in any country, according to the release.

"We remain confident in ozanimod's clinical profile demonstrated in the pivotal program in relapsing forms of multiple sclerosis," said Jay Backstrom, MD, chief medical officer and head of Global Regulatory Affairs, Celgene, said in the release. "We will work with the FDA to expeditiously address all outstanding items and bring this important medicine to patients."

In February 2017, Celgene announced phase 3 findings that suggest ozanimod could reduce the frequency of relapse.

Related Coverage: Ozanimod Reduces Frequency of Relapsing Multiple Sclerosis

The randomized, double-blind, double-dummy, active-controlled, phase 3 SUNBEAM study compared ozanimod with interferon β-1a (Avonex) in 1346 patients with relapsing MS. The results of the study showed that ozanimod met its primary endpoint in reducing the annualized relapse rate of relapsing MS compared with interferon β-1a.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
Image credit: gamjai - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.